摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

prochlorperazine hydrochloride

中文名称
——
中文别名
——
英文名称
prochlorperazine hydrochloride
英文别名
3-Chlor-10-(3-4'-methyl-1'-piperazinylpropyl)-phenthiazin;3-Chlor-10-(3-4'-methyl-1'-piperazinylpropyl)-phenthiazin Dihydrochlorid;Prochlorperazin-hydrochlorid;Prochlorperazine dihydrochloride;2-chloro-10-[3-(4-methyl-piperazin-1-yl)-propyl]-10H-phenothiazine; dihydrochloride;2-chloro-10-[3-(4-methyl-piperazino)-propyl]-phenothiazine; dihydrochloride;2-Chlor-10-[3-(4-methyl-piperazino)-propyl]-phenothiazin; Dihydrochlorid;Prochlorperazine Base;2-chloro-10-[3-(4-methylpiperazin-1-yl)propyl]phenothiazine;hydrochloride
prochlorperazine hydrochloride化学式
CAS
——
化学式
C20H24ClN3S*2ClH
mdl
——
分子量
446.872
InChiKey
CQEDGWAZGXCLAP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5.0
  • 重原子数:
    26
  • 可旋转键数:
    4
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.4
  • 拓扑面积:
    35
  • 氢给体数:
    1
  • 氢受体数:
    4

反应信息

  • 作为反应物:
    描述:
    2-(邻甲苯)吡啶prochlorperazine hydrochloride 在 C17H24N5Ru(1+)*F6P(1-)potassium acetatepotassium carbonate 作用下, 以 N-甲基吡咯烷酮 为溶剂, 反应 48.0h, 以85%的产率得到[2-(o-Tolyl)pyridine]-[prochlorperazine]
    参考文献:
    名称:
    [EN] PROCESS FOR FORMING A CARBON-CARBON BOND
    [FR] PROCÉDÉ DE FORMATION D'UNE LIAISON CARBONE-CARBONE
    摘要:
    一种形成碳-碳键的工艺,用于将第一化合物中的芳基或杂芳基团与第二化合物中的芳基或杂芳基团偶联,该工艺包括在存在公式(I)的中性或阳离子钌(II)催化剂的催化有效量下,使第一化合物与第二化合物反应:
    公开号:
    WO2019215426A1
点击查看最新优质反应信息

文献信息

  • Compositions for Nasal Administration of Phenothiazines
    申请人:GUY David
    公开号:US20100215730A1
    公开(公告)日:2010-08-26
    Provided herein are pharmaceutical compositions comprising phenothiazines or derivatives thereof that are formulated for nasal administration. Also provided herein are methods of utilizing the same.
    本文提供了一种含有苯并噻唑或其衍生物的药物组合物,该药物组合物适用于鼻腔给药。本文还提供了使用该药物组合物的方法。
  • Low molecular weight polymers
    申请人:Huang Yujin
    公开号:US20050238618A1
    公开(公告)日:2005-10-27
    The invention relates to a procedure for purifying low molecular weight polylactic acid polymers by use of reduced temperature liquid-liquid phase separation of the polymers in methanol, ethanol or isopropanol based solvents, compositions comprising the polymers and methods of using the same.
    本发明涉及一种用于通过在甲醇、乙醇或异丙醇基溶剂中使用降温液-液相分离来纯化低分子量聚乳酸聚合物的方法,以及包含该聚合物的组合物和使用方法。
  • Method for ameliorating male erectile dysfunction
    申请人:——
    公开号:US20040092493A1
    公开(公告)日:2004-05-13
    Impotence can be ameliorated without substantial undesirable side effects by nasal administration of apomorphine, optionally with an antiemetic agent present in an amount sufficient to substantially reduce nausea symptoms that may be associated with the use of apomorphine.
    阳痿可以通过鼻腔给予阿泼莫啡来改善,选择性地加入抗恶心剂以足够减轻可能与阿泼莫啡使用相关的恶心症状,而不会产生重大的不良副作用。
  • Apomorphine-containing dosage form for ameliorating male erectile dysfunction
    申请人:——
    公开号:US20030073715A1
    公开(公告)日:2003-04-17
    Impotence can be ameliorated without substantial undesirable side effects by nasal administration of apomorphine, optionally with an antiemetic agent present in an amount sufficient to substantially reduce nausea symptoms that may be associated with the use of apomorphine.
    阳痿可以通过鼻腔给予阿泼莫啡进行改善,且在必要时可以加入足够量的抗恶心药物以显著减少可能与阿泼莫啡使用相关的恶心症状,而不会产生重大的不良副作用。
  • Injectable suspensions having improved injectability properties
    申请人:Alkermes Controlled Therapeutics, Inc.
    公开号:EP1754469A1
    公开(公告)日:2007-02-21
    Injectable compositions having improved injectability. The injectable compositions include microparticles in an aqueous injection vehicle having a viscosity of at least 20 cp at 20 °C. The increased viscosity of the injection vehicle that constitutes the fluid phase of the suspension significantly reduces in vivo injectability failures. The injectable compositions can be made by mixing dry microparticles with an aqueous injection vehicle to form a suspension, and then mixing the suspension with a viscosity enhancing agent to increase viscosity of the fluid phase of the suspension to the desired level for improved injectability.
    注射剂组合物具有更好的可注射性。可注射组合物包括水性注射载体中的微颗粒,该注射载体在 20 °C 时的粘度至少为 20 cp。构成悬浮液液相的注射载体粘度增加,可显著降低体内注射失败率。可注射组合物可通过将干微颗粒与水性注射载体混合形成悬浮液,然后将悬浮液与增粘剂混合,以将悬浮液流体相的粘度增加到所需水平,从而改善可注射性。
查看更多